F J Backes1, A S Felix2, M Plante3, J Grégoire4, S A Sullivan5, E C Rossi5, E J Tanner6, K I Stewart7, P T Soliman7, R W Holloway8, N R Abu-Rustum9, M M Leitao9. 1. The Ohio State University, James Cancer Hospital, Columbus, OH, USA. Electronic address: Floor.backes@osumc.edu. 2. The Ohio State University College of Public Health, Columbus, OH, USA. 3. Laval University, L'Hotel-Dieu de Quebec, Quebec City, QC, Canada. 4. L'Hotel-Dieu de Quebec, Quebec City, QC, Canada. 5. University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 6. Northwestern University, Chicago, IL, USA. 7. The University of Texas, MD Anderson Cancer Center, Houston, TX, USA. 8. AdventHealth Cancer Institute, Orlando, FL, USA. 9. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract
OBJECTIVES: To assess associations between treatment and recurrence-free survival (RFS) among patients with isolated tumor cells (ITCs) in sentinel lymph nodes (SLN) and otherwise stage I/II endometrioid endometrial cancer (EC). METHODS: A multi-institutional retrospective study of patients with SLN ITCs (<200 cells and < 0.2 mm) was performed. Only patients with otherwise stage I/II EC, endometrioid histology, and no evidence of micro-or macrometastases were included. Univariate and multivariable Cox proportional hazard models were used to evaluate associations between treatment, tumor characteristics, and RFS. RESULTS: 175 patients were included. Median follow up time was 31 months. 39% stage IB and 12% stage II disease. 76 (43%) received no adjuvant therapy or vaginal brachytherapy only (NAT/VBT), 21 (12%) had external beam radiation (EBRT), and 78 (45%) received chemotherapy +/- radiation. Patients who received chemotherapy more often had tumors with deep myoinvasion, lymphovascular space invasion (LVSI), and higher grade. Nine (5.1%) patients recurred; 5 distant, 3 retroperitoneal, and 1 vaginal. Extra-vaginal recurrences were similar in patients with or without chemotherapy (5.2% vs 3.8%, p = 0.68). After controlling for stage, LVSI and grade, chemotherapy and EBRT were not associated with RFS (HR = 0.63, 95%CI 0.11-3.52, and HR = 0.90, 95%CI 0.22-3.61, respectively). Type of lymph node dissection and ITC detection method were not associated with RFS. CONCLUSIONS: Risk of retroperitoneal and/or distant recurrence is low (4.6%) for patients with stage I/II endometrioid EC and ITCs in SLNs regardless of treatment. Our preliminary data suggests that adjuvant therapy may not be significantly associated with RFS. However, longer follow-up time and a larger sample size are needed before definitive recommendations regarding adjuvant therapy for patients with EC and only ITCs in SLN can be made.
OBJECTIVES: To assess associations between treatment and recurrence-free survival (RFS) among patients with isolated tumor cells (ITCs) in sentinel lymph nodes (SLN) and otherwise stage I/II endometrioid endometrial cancer (EC). METHODS: A multi-institutional retrospective study of patients with SLN ITCs (<200 cells and < 0.2 mm) was performed. Only patients with otherwise stage I/II EC, endometrioid histology, and no evidence of micro-or macrometastases were included. Univariate and multivariable Cox proportional hazard models were used to evaluate associations between treatment, tumor characteristics, and RFS. RESULTS: 175 patients were included. Median follow up time was 31 months. 39% stage IB and 12% stage II disease. 76 (43%) received no adjuvant therapy or vaginal brachytherapy only (NAT/VBT), 21 (12%) had external beam radiation (EBRT), and 78 (45%) received chemotherapy +/- radiation. Patients who received chemotherapy more often had tumors with deep myoinvasion, lymphovascular space invasion (LVSI), and higher grade. Nine (5.1%) patients recurred; 5 distant, 3 retroperitoneal, and 1 vaginal. Extra-vaginal recurrences were similar in patients with or without chemotherapy (5.2% vs 3.8%, p = 0.68). After controlling for stage, LVSI and grade, chemotherapy and EBRT were not associated with RFS (HR = 0.63, 95%CI 0.11-3.52, and HR = 0.90, 95%CI 0.22-3.61, respectively). Type of lymph node dissection and ITC detection method were not associated with RFS. CONCLUSIONS: Risk of retroperitoneal and/or distant recurrence is low (4.6%) for patients with stage I/II endometrioid EC and ITCs in SLNs regardless of treatment. Our preliminary data suggests that adjuvant therapy may not be significantly associated with RFS. However, longer follow-up time and a larger sample size are needed before definitive recommendations regarding adjuvant therapy for patients with EC and only ITCs in SLN can be made.
Authors: Floor J Backes; David Cohen; Ritu Salani; David E Cohn; David M O'Malley; Emily Fanning; Adrian A Suarez; Jeffrey M Fowler Journal: Gynecol Oncol Date: 2019-04-04 Impact factor: 5.482
Authors: Emma C Rossi; Lynn D Kowalski; Jennifer Scalici; Leigh Cantrell; Kevin Schuler; Rabbie K Hanna; Michael Method; Melissa Ade; Anastasia Ivanova; John F Boggess Journal: Lancet Oncol Date: 2017-02-01 Impact factor: 41.316
Authors: Joyce N Barlin; Fady Khoury-Collado; Christine H Kim; Mario M Leitao; Dennis S Chi; Yukio Sonoda; Kaled Alektiar; Deborah F DeLair; Richard R Barakat; Nadeem R Abu-Rustum Journal: Gynecol Oncol Date: 2012-02-22 Impact factor: 5.482
Authors: Jessica A Kennard; Amanda J Stephens; Sarfraz Ahmad; Xiang Zhu; Charanjeet Singh; Nathalie D McKenzie; James E Kendrick; Robert W Holloway Journal: Gynecol Oncol Date: 2019-04-23 Impact factor: 5.482
Authors: Caryn M St Clair; Ane Gerda Z Eriksson; Jennifer A Ducie; Elizabeth L Jewell; Kaled M Alektiar; Martee L Hensley; Robert A Soslow; Nadeem R Abu-Rustum; Mario M Leitao Journal: Ann Surg Oncol Date: 2015-12-29 Impact factor: 5.344
Authors: D Cibula; N R Abu-Rustum; L Dusek; M Zikán; A Zaal; L Sevcik; G G Kenter; D Querleu; R Jach; A S Bats; G Dyduch; P Graf; J Klat; J Lacheta; C J L M Meijer; E Mery; R Verheijen; R P Zweemer Journal: Gynecol Oncol Date: 2011-11-25 Impact factor: 5.482
Authors: Edward Tanner; Allison Puechl; Kimberly Levinson; Laura J Havrilesky; Abdulrahman Sinno; Angeles Alvarez Secord; Amanda N Fader; Paula S Lee Journal: Gynecol Oncol Date: 2017-10-19 Impact factor: 5.482
Authors: Stephanie M de Boer; Melanie E Powell; Linda Mileshkin; Dionyssios Katsaros; Paul Bessette; Christine Haie-Meder; Petronella B Ottevanger; Jonathan A Ledermann; Pearly Khaw; Alessandro Colombo; Anthony Fyles; Marie-Helene Baron; Ina M Jürgenliemk-Schulz; Henry C Kitchener; Hans W Nijman; Godfrey Wilson; Susan Brooks; Silvestro Carinelli; Diane Provencher; Chantal Hanzen; Ludy C H W Lutgens; Vincent T H B M Smit; Naveena Singh; Viet Do; Romerai D'Amico; Remi A Nout; Amanda Feeney; Karen W Verhoeven-Adema; Hein Putter; Carien L Creutzberg Journal: Lancet Oncol Date: 2018-02-12 Impact factor: 41.316